Exosome packaging of nucleic acids
A method for preparing exosomes or exosome-like vesicles packaged with a nucleic acid of interest is provided. In certain embodiments, the method may comprise: introducing into an exosome-producing cell a nucleic acid construct comprising the nucleic acid sequence of interest incorporated in a pre-miR-451 structural mimic, and allowing the cell to produce exosomes. Nucleic acid constructs, compositions, and uses thereof are also provided.
1. A method for producing exosomes or exosome-like vesicles comprising a gene silencing nucleic acid, a nucleic acid of interest, or a precursor thereof, said method comprising:
introducing into an exosome-producing cell, or expressing in an exosome-producing cell, a nucleic acid construct comprising the gene silencing nucleic acid, nucleic acid of interest, or a precursor thereof, incorporated within a pre-miR-451 structural mimic;
treating the exosome-producing cell with a lysosomal or autophagy inhibitor;
producing exosomes or exosome-like vesicles from the cell; and
collecting or enriching the produced exosomes or exosome-like vesicles.
2. The method according to claim 1 , wherein the pre-miR-451 structural mimic comprises a stem-loop secondary structure having a blunt end, a 5′ overhang, a 3′ overhang, or 5′ and 3′ loose ends, and having an overall length of about 25-54 nucleotides (nt).
3. The method according to claim 1 , wherein the pre-miR-451 structural mimic comprises a stem-loop secondary structure having an overall loop length of about 4-8 nt.
4. The method according to claim 1 , wherein the pre-miR-451 structural mimic comprises a stem-loop secondary structure having at least one base pair mismatch in the stem.
5. The method according to claim 1 , wherein the pre-miR-451 structural mimic comprises a stem-loop secondary structure with a 3′ end which extends to, or before, or after an Ago2 cleavage position, such that the pre-miR-451 structural mimic includes a 5′ overhang portion and a 3′ base-paired portion.
6. The method according to claim 1 , wherein the pre-miR-451 structural mimic comprises a single-stranded structure including a 3′ portion, mimicking mature miR-451.
7. The method according to claim 6 , wherein the pre-miR-451 structural mimic is about 22-35 nt in length.
8. The method according to claim 1 , wherein the cell is an embryonic stem cell (ESC) clone H1 or H9 cell, a mesenchymal stem cell (MSC), a cell having low Ago2 expression or activity levels, a primary human mesenchymal stem cell, a primary mouse macrophage, a human breast cancer cell line, a mouse or human neuronal cell line, a mouse astrocyte cell line, a mouse microglia cell line, a mouse motor neuron cell line, a HeLa cell, a mouse embryonic fibroblast, or a mouse dendritic cell.
9. The method according to claim 1 , wherein the gene silencing nucleic acid is, or is derived from, a miRNA, shRNA, Crispr guide RNA, or siRNA.
10. The method according to claim 1 , wherein the cell is cultured in serum-free media, or in exosome-depleted serum media, while producing the exosomes or exosome-like vesicles.
11. The method according to claim 2 , wherein the pre-miR-451 structural mimic further comprises an overall length of 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 nt.
12. A method for producing exosomes or exosome-like vesicles comprising a gene silencing nucleic acid, a nucleic acid of interest, or a precursor thereof, said method comprising:
introducing into an exosome-producing cell, or expressing in an exosome-producing cell, a nucleic acid construct comprising the gene silencing nucleic acid, nucleic acid of interest, or a precursor thereof, incorporated within a pre-miR-451 structural mimic;
producing exosomes or exosome-like vesicles from the cell; and
collecting or enriching the produced exosomes or exosome-like vesicles,
wherein the pre-miR-451 structural mimic comprises a stem-loop secondary structure having at least one base pair mismatch in the stem, and wherein at least one base pair mismatch in the stem is positioned within the first three base pairs adjacent to a Drosha cleavage site.
13. A method for producing exosomes or exosome-like vesicles comprising a gene silencing nucleic acid, a nucleic acid of interest, or a precursor thereof, said method comprising:
introducing into an exosome-producing cell, or expressing in an exosome-producing cell, a nucleic acid construct comprising the gene silencing nucleic acid, nucleic acid of interest, or a precursor thereof, incorporated within a pre-miR-451 structural mimic;
producing exosomes or exosome-like vesicles from the cell; and
collecting or enriching the produced exosomes or exosome-like vesicles,
wherein the pre-miR-451 structural mimic comprises a single-stranded structure including a 3′ portion, which is a loop-derived sequence, mimicking mature miR-451.
14. A method for producing exosomes or exosome-like vesicles comprising a gene silencing nucleic acid, a nucleic acid of interest, or a precursor thereof, said method comprising:
introducing into an exosome-producing cell, or expressing in an exosome-producing cell, a nucleic acid construct comprising the gene silencing nucleic acid, nucleic acid of interest, or a precursor thereof, incorporated within a pre-miR-451 structural mimic;
producing exosomes or exosome-like vesicles from the cell; and
collecting or enriching the produced exosomes or exosome-like vesicles,
wherein the pre-miR-451 structural mimic comprises a single-stranded structure including a 3′ portion, mimicking mature miR-451, and wherein the pre-miR-451 structural mimic is about 23-24 nt in length.
15. The method according to claim 8 , wherein the cell is a human breast cancer cell line MDA-MB-231, a mouse or human neuronal cell line Neuro2a or SHSY, a mouse astrocyte cell line C8 Da or SIM, a mouse microglia cell line BV2, a mouse motor neuron cell line NSC-34 or MN-1, a HeLa cell, a mouse embryonic fibroblast, or a mouse dendritic cell line JAWS II.